EB Research Partnership
  • Epidermolysis Bullosa
    • What is EB?
    • Life with EB
    • Resources
  • Research
    • Our Impact
    • Scientific Advisory Board
    • Clinical Trials >
      • Filsuvez
      • Vyjuvek
      • ZEVASKYN
    • Town Halls
    • Apply for a Grant
  • Get Involved
    • Donate
    • Sponsor
    • EB Active
    • Events
    • The Effect
    • Shop
    • Give Cryptocurrency
    • Give Stocks
    • Give through Donor Advised Funds (DAF)
    • Accelerator Fund
  • Media
    • Matter of Time Film
    • Press
    • Videos
  • About Us
    • Our Mission
    • Financials
    • Venture Philanthropy
    • Supporter Spotlights
    • Leadership >
      • Board of Directors
      • Staff
  • Donate

krystal biotech x ebrp

Picture

Landmark victory!

The FDA announced their approval of Krystal Biotech’s VYJUVEK™ for the treatment of Dystrophic Epidermolysis Bullosa (DEB). EB Research Partnership (“EBRP”) invested in Krystal Biotech by way of a private placement after Krystal’s Biotech’s initial public offering in 2017 using EBRP’s Venture Philanthropy model. This is not only the first-ever FDA approved treatment for those battling DEB, but also the first FDA approved topical, redosable gene therapy.
 
400 million people around the world are affected by a rare disease. 95% of rare diseases lack an FDA approved treatment or cure. Today, DEB warriors around the world cross into the 5% with the approval of Krystal Biotech’s VYJUVEK. VYJUVEK is a non-invasive, topical, redosable gene therapy.

A SCALABLE MODEL THAT’S BREAKING GROUND
This FDA approval marks a milestone in EBRP’s mission to discover treatments and a cure for EB. It provides validation for our scalable and sustainable Venture Philanthropy business model and most importantly creates hope for families around the world battling EB every day.
 
EBRP’s Venture Philanthropy business model has been highlighted for its leadership by Harvard Business School, Yale University, and MIT in helping to fast-track not only a cure for EB but therapies that could affect thousands of other rare diseases.
 
EBRP invested in Krystal Biotech in 2017, shortly after Krystal Biotech’s initial public offering of common stock. The investment was made via a private placement of Krystal Biotech’s common stock, and as part of the stock purchase agreement, Krystal Biotech committed to commence a Phase I clinical trial of VYJUVEK. The funding followed the highly competitive application and screening process overseen by EBRP’s Scientific Advisory Board (SAB), which is composed of leading scientists and physicians. EBRP was able to generate a more than double return on its investment and reinvest that capital back into more EB projects.

DONATE TO FUND FURTHER LIFE-SAVING RESEARCH
READ EBRP'S PRESS RELEASE

Connect with krystal

Call 1-844-5-KRYSTAL to connect with Krystal Biotech to learn more about dystrophic epidermolysis bullosa (DEB). Krystal also has comprehensive resources on Dystrophic Epidermolysis Bullosa (DEB) on their site.
CONNECT WITH KRYSTAL
MORE ON VYJUVEK

read the latest news on krystal

Picture
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa!
READ KRYSTAL PRESS RELEASE
READ STANFORD ARTICLE

about eb research partnership

Our Mission
We're the largest global nonprofit funding research to discover treatments and cures for Epidermolysis Bullosa (EB), a group of rare and life-threatening genetic disorders that affect the body's largest organ - the skin. Children with EB lack proteins that bind the skin's two layers together, causing it to blister and shear off from even the slightest friction. To date, we've funded 120+ research projects, transforming the clinical landscape from just 2 clinical trials in EB when we were founded to 40 today.

Our Model
​At EBRP, we pride ourselves on innovating to accelerate the path to a cure for EB. Through our Venture Philanthropy model, we negotiate a financial interest in the research we fund. If that research leads to a commercially successful therapy, we use our returns to fund additional EB research. In other words, your donation has the potential to grow to multiples of its original value. 
GET EB ACTIVE
DONATE
CONNECT WITH EBRP

EB Research Partnership

244 Madison Ave Ste 104
New York, NY 10016 
[email protected]
646-844-0902
Careers
​
Donor Privacy Policy

Curator Privacy Policy

Curator Terms of Use
Donate

Contact Us
​

​Our Mission

​Shop

Press
Picture

COPYRIGHT @2025 EB RESEARCH PARTNERSHIP. ALL RIGHTS RESERVED. EB RESEARCH PARTNERSHIP IS A 501(C)(3) NON PROFIT.

  • Epidermolysis Bullosa
    • What is EB?
    • Life with EB
    • Resources
  • Research
    • Our Impact
    • Scientific Advisory Board
    • Clinical Trials >
      • Filsuvez
      • Vyjuvek
      • ZEVASKYN
    • Town Halls
    • Apply for a Grant
  • Get Involved
    • Donate
    • Sponsor
    • EB Active
    • Events
    • The Effect
    • Shop
    • Give Cryptocurrency
    • Give Stocks
    • Give through Donor Advised Funds (DAF)
    • Accelerator Fund
  • Media
    • Matter of Time Film
    • Press
    • Videos
  • About Us
    • Our Mission
    • Financials
    • Venture Philanthropy
    • Supporter Spotlights
    • Leadership >
      • Board of Directors
      • Staff
  • Donate